Benzinga··PrnewswireBrainStorm Charts Recovery Path With $2M Funding as NurOwn Advances to Pivotal ALS Trial
BrainStorm Cell Therapeutics reported $10.3M net loss for 2025 while securing $2M financing and advancing NurOwn into Phase 3b ALS study following FDA clearance.
BCLIfinancial resultsprivate placement